Bukwang Pharmaceutical said Wednesday that it has acquired a patent for JM-010, a drug candidate for levodopa-induced dyskinesia (LID).

The drug, developed by Contera Pharma, a Denmark bio-venture acquired by the company in 2014, is a new drug candidate that treats LID, a disease that many Parkinson's disease patients suffer from after long-term administration of levodopa, a standard treatment for the illness.

The company had filed three international patents for LID treatment JM-010, including patents for application, composition, and formulation and metabolism. Starting with its patent registration in the U.S., the company has completed patent registration for application and composition of JM-010 in 32 European countries, Australia, China and Japan. Formulation patents are also already registered in 21 European countries, Australia, China and Japan.

Bukwang Pharma has received positive results in phase 2a clinical trials and is preparing to conduct phase 2b clinical trials in the U.S. and Europe.

“The company expects that the registration of JM-010 patents in major countries, including the U.S. and Europe, will become a steppingstone in the company’s global advance,” a company official said. “The patents have also shown the originality of our technology.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>